Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

医学 曲妥珠单抗 曲妥珠单抗 转移性乳腺癌 内科学 肿瘤科 乳腺癌 癌症
作者
Sara A. Hurvitz,Roberto Hegg,Wei‐Pang Chung,Seock‐Ah Im,William Jacot,Vinod Ganju,Joanne Wing Yan Chiu,Binghe Xu,Erika Hamilton,Srinivasan Madhusudan,Hiroji Iwata,Sevilay Altıntaş,Jan‐Willem Henning,Giuseppe Curigliano,José Manuel Pérez-García,Sung‐Bae Kim,Vanessa Petry,Chiun‐Sheng Huang,Wěi Li,Jean‐Sébastien Frénel
出处
期刊:The Lancet [Elsevier BV]
卷期号:401 (10371): 105-117 被引量:430
标识
DOI:10.1016/s0140-6736(22)02420-5
摘要

An improvement in progression-free survival was shown with trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer in the progression-free survival interim analysis of the DESTINY-Breast03 trial. The aim of DESTINY-Breast03 was to compare the efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine.This open-label, randomised, multicentre, phase 3 trial was done in 169 study centres in North America, Asia, Europe, Australia, and South America. Eligible patients were aged 18 or older, had HER2-positive unresectable or metastatic breast cancer previously treated with trastuzumab and a taxane, had an Eastern Cooperative Oncology Group performance status 0-1, and at least one measurable lesion per Response Evaluation Criteria in Solid Tumours version 1.1. Patients were randomly assigned (1:1) to receive trastuzumab deruxtecan 5·4 mg/kg or trastuzumab emtansine 3·6 mg/kg, both administered by intravenous infusion every 3 weeks. Randomisation was stratified by hormone receptor status, previous treatment with pertuzumab, and history of visceral disease, and was managed through an interactive web-based system. Within each stratum, balanced block randomisation was used with a block size of four. Patients and investigators were not masked to the treatment received. The primary endpoint was progression-free survival by blinded independent central review. The key secondary endpoint was overall survival and this prespecified second overall survival interim analysis reports updated overall survival, efficacy, and safety results. Efficacy analyses were performed using the full analysis set. Safety analyses included all randomly assigned patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT03529110.Between July 20, 2018, and June 23, 2020, 699 patients were screened for eligibility, 524 of whom were enrolled and randomly assigned to receive trastuzumab deruxtecan (n=261) or trastuzumab emtansine (n=263). Median duration of study follow-up was 28·4 months (IQR 22·1-32·9) with trastuzumab deruxtecan and 26·5 months (14·5-31·3) with trastuzumab emtansine. Median progression-free survival by blinded independent central review was 28·8 months (95% CI 22·4-37·9) with trastuzumab deruxtecan and 6·8 months (5·6-8·2) with trastuzumab emtansine (hazard ratio [HR] 0·33 [95% CI 0·26-0·43]; nominal p<0·0001). Median overall survival was not reached (95% CI 40·5 months-not estimable), with 72 (28%) overall survival events, in the trastuzumab deruxtecan group and was not reached (34·0 months-not estimable), with 97 (37%) overall survival events, in the trastuzumab emtansine group (HR 0·64; 95% CI 0·47-0·87]; p=0·0037). The number of grade 3 or worse treatment-emergent adverse events was similar in patients who received trastuzumab deruxtecan versus trastuzumab emtansine (145 [56%] patients versus 135 [52%] patients). Adjudicated drug-related interstitial lung disease or pneumonitis occurred in 39 (15%) patients treated with trastuzumab deruxtecan and eight (3%) patients treated with trastuzumab emtansine, with no grade 4 or 5 events in either group.Trastuzumab deruxtecan showed a significant improvement in overall survival versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer, as well as the longest reported median progression-free survival, reaffirming trastuzumab deruxtecan as the standard of care in the second-line setting. A manageable safety profile of trastuzumab deruxtecan was confirmed with longer treatment duration.Daiichi Sankyo and AstraZeneca.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酷波er应助lh采纳,获得10
1秒前
小郑发布了新的文献求助10
1秒前
clock完成签到 ,获得积分10
1秒前
66完成签到,获得积分10
2秒前
Orange应助jinkk采纳,获得10
2秒前
RuiLi完成签到,获得积分10
2秒前
煎饼狗子关注了科研通微信公众号
2秒前
xxxxxb完成签到,获得积分10
2秒前
英姑应助糖糖采纳,获得10
2秒前
淡淡小土豆完成签到 ,获得积分10
3秒前
伶俐的高烽完成签到 ,获得积分10
4秒前
candy6663339完成签到,获得积分10
4秒前
4秒前
gao完成签到 ,获得积分0
5秒前
打打应助科研通管家采纳,获得10
5秒前
完美世界应助科研通管家采纳,获得10
5秒前
科研通AI2S应助科研通管家采纳,获得30
5秒前
英姑应助科研通管家采纳,获得10
5秒前
Akim应助科研通管家采纳,获得20
5秒前
sota完成签到,获得积分10
5秒前
无花果应助科研通管家采纳,获得10
5秒前
5秒前
5秒前
Ava应助科研通管家采纳,获得10
5秒前
爆米花应助科研通管家采纳,获得10
6秒前
SciGPT应助科研通管家采纳,获得10
6秒前
6秒前
田様应助科研通管家采纳,获得10
6秒前
6秒前
6秒前
6秒前
6秒前
6秒前
6秒前
6秒前
英俊的铭应助科研通管家采纳,获得10
6秒前
灰色与青完成签到,获得积分10
7秒前
bkagyin应助ylw采纳,获得10
7秒前
星辰大海应助kcmat采纳,获得10
8秒前
9秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds第二卷 1200
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038657
求助须知:如何正确求助?哪些是违规求助? 3576306
关于积分的说明 11375198
捐赠科研通 3306108
什么是DOI,文献DOI怎么找? 1819379
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815066